Arranta Bio, a microbiome contract development and manufacturing organization (CDMO), has announced the mechanical completion of GMP suites at its Watertown, MA commercial-ready facility.
 
Arranta is investing more than $100 million in 2020 to establish a multi-product, commercial-ready manufacturing facility that will supply live biotherapeutic products (LBPs) to microbiome innovator companies. The Watertown facility has been designed to the highest specifications for advanced biologics production.
 
“We are grateful to the Arranta team and to our construction management partner, DC Beane and Associates Construction Company, who specializes in the construction and development of life science facilities, and the numerous sub-contractors who have supported Arranta and worked through the pandemic in a safe and efficient manner to keep our commercial-ready manufacturing facility build-out on schedule. This is a remarkable accomplishment that will enable Arranta to supply vital products to patients in need and provide more than 200 new product development, manufacturing and operations jobs,” said Mark Bamforth, president and CEO of Arranta Bio.
 
Arranta is also expanding process development, and GMP capacity at its early-clinical supply facility in Gainesville, FL.